T. de La Motte Rouge

Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor

T. de La Motte Rouge, Patricia Pautier, Pierre Duvillard et al. · Annals of Oncology · 2008 · 97 citations · Full text

Medicine, Gynecology, Surgery +12

Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)

Liang Xu, Adrien Briaux, Véronique Becette et al. · Journal of Hematology & Oncology · 2018 · 29 citations · Full text

Medicine, Immunology, Oncology +17

Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network

Fanny Derquin, Anne Floquet, Anne Claire Hardy-Bessard et al. · Gynecologic Oncology · 2020 · 25 citations · Full text

Medicine, Gynecology, Oncology +16

MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors

Cécile Vicier, Nicolás Isambert, C. Cropet et al. · ESMO Open · 2022 · 16 citations · Full text

Medicine, Oncology, Pharmacology +11

“Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors”

François Gernier, Djihane Ahmed-Lecheheb, Patricia Pautier et al. · BMC Cancer · 2021 · 10 citations · Full text

Medicine, Gynecology, Oncology +17